Background:
The presence of
persistent mild
inflammation is
widely considered to
provide the
immunopathogenic
basis for
bronchial,nasal, or
sinusal inflammation
between critical
phases and in
asymptomatic
periods. Exhaled
nitric oxide (NO) is
currently the most
reliable marker of
rhinobronchial infl
ammation, but its
routine assessment
is difficult as the
test is available
only in highly
specialized centers.
Objective:
The aim of this
study was to
evaluate the
agreement between a
new diagnostic
method (extracellular
electrical impedance
tomography) and
immunological and
clinical symptom
scores, anterior
rhinomanometry, peak
expiratory flow rate
(PEFR), serum
eosinophil cationic
protein (ECP) level,
and blood eosinophil
count in the
clinical monitoring
of respiratory tract
infl ammation before
and after treatment
of asthma or
rhinitis.
Patients and
Methods:
Eighty-seven
patients were
studied; 73 had mild
persistent asthma (PEFR
≥20% below
predicted) and 14
had rhinitis. At
baseline (T0), the
patients underwent a
medical examination
to record symptom
scores, PEFR,
anterior
rhinomanometry, an
extracellular
electrolytic
conductivity test (bioimpedance
tomography), serum
ECP level and blood
eosinophil count.
Appropriate
treatment was
prescribed,
following the
guidelines of the
Global Initiative
for Asthma and the
Allergic Rhinitis
and Its Impact on
Asthma. After 21
days of therapy
(T1), the patients
were re-evaluated
for the same
parameters.
Results and
Conclusions:
This study
demonstrates the
good agreement
(Cohens κ = 0.689)
between the symptom
scores of patients
with rhinitis and
the fi ndings of
extracellular
tomography and very
good agreement (κ =
0.846) between
symptom scores of
asthma patients and
extracellular
tomography. These fi
ndings validate the
use of this new
technique for the
real-time monitoring
and adjustment of
treatment in these
clinical settings.
Key words:
Inflammation, mild
persistent. Asthma.
Rhinitis.
Extracellular
electrical impedance
tomography.
Bioimpedance.
Artificial neural
network.
Allergo-Midax. |